Monoclonal antibody
A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
It is possible to produce monoclonal antibodies that specifically bind to almost any suitable substance; they can then serve to detect or purify it. This capability has become an investigative tool in biochemistry, molecular biology, and medicine. Monoclonal antibodies are used in the diagnosis of illnesses such as cancer and infections[3] and are used therapeutically in the treatment of e.g. cancer and inflammatory diseases.
History
In the early 1900s,
By the 1970s,
In 1988, Gregory Winter and his team pioneered the techniques to humanize monoclonal antibodies,[8] eliminating the reactions that many monoclonal antibodies caused in some patients. By the 1990s research was making progress in using monoclonal antibodies therapeutically, and in 2018, James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation, using monoclonal antibodies that prevent inhibitory linkages.[9]
The translational work needed to implement these ideas is credited to Lee Nadler. As explained in an NIH article, "He was the first to discover monoclonal antibodies directed against human B-cell–specific antigens and, in fact, all the known human B-cell–specific antigens were discovered in his laboratory. He is a true translational investigator, since he used these monoclonal antibodies to classify human B-cell leukemia and lymphomas as well as to create therapeutic agents for patients. . . More importantly, he was the first in the world to administer a monoclonal antibody to a human (a patient with B-cell lymphoma)."[10]
Production
Hybridoma development
Much of the work behind production of monoclonal antibodies is rooted in the production of hybridomas, which involves identifying antigen-specific plasma/plasmablast cells that produce antibodies specific to an antigen of interest and
The selective culture medium is called
This mixture of cells is then diluted and clones are grown from single parent cells on microtitre wells. The antibodies secreted by the different clones are then assayed for their ability to bind to the antigen (with a test such as ELISA or antigen microarray assay) or immuno-dot blot. The most productive and stable clone is then selected for future use.
The hybridomas can be grown indefinitely in a suitable cell culture medium. They can also be injected into mice (in the peritoneal cavity, surrounding the gut). There, they produce tumors secreting an antibody-rich fluid called ascites fluid.
The medium must be enriched during in vitro selection to further favour hybridoma growth. This can be achieved by the use of a layer of feeder fibrocyte cells or supplement medium such as briclone. Culture-media conditioned by macrophages can be used. Production in cell culture is usually preferred as the ascites technique is painful to the animal. Where alternate techniques exist, ascites is considered unethical.[14]
Novel mAb development technology
Several monoclonal antibody technologies have been developed recently,[15] such as phage display,[16] single B cell culture,[17] single cell amplification from various B cell populations[18][19][20][21][22] and single plasma cell interrogation technologies. Different from traditional hybridoma technology, the newer technologies use molecular biology techniques to amplify the heavy and light chains of the antibody genes by PCR and produce in either bacterial or mammalian systems with recombinant technology. One of the advantages of the new technologies is applicable to multiple animals, such as rabbit, llama, chicken and other common experimental animals in the laboratory.
Purification
After obtaining either a media sample of cultured hybridomas or a sample of ascites fluid, the desired antibodies must be extracted. Cell culture sample contaminants consist primarily of media components such as growth factors, hormones and transferrins. In contrast, the in vivo sample is likely to have host antibodies, proteases, nucleases, nucleic acids and viruses. In both cases, other secretions by the hybridomas such as cytokines may be present. There may also be bacterial contamination and, as a result, endotoxins that are secreted by the bacteria. Depending on the complexity of the media required in cell culture and thus the contaminants, one or the other method (in vivo or in vitro) may be preferable.
The sample is first conditioned, or prepared for purification. Cells, cell debris, lipids, and clotted material are first removed, typically by centrifugation followed by
Most of the charged impurities are usually
Transferrin can instead be removed by
A much quicker, single-step method of separation is protein A/G affinity chromatography. The antibody selectively binds to protein A/G, so a high level of purity (generally >80%) is obtained. However, this method may be problematic for antibodies that are easily damaged, as harsh conditions are generally used. A low pH can break the bonds to remove the antibody from the column. In addition to possibly affecting the product, low pH can cause protein A/G itself to leak off the column and appear in the eluted sample. Gentle elution buffer systems that employ high salt concentrations are available to avoid exposing sensitive antibodies to low pH. Cost is also an important consideration with this method because immobilized protein A/G is a more expensive resin.
To achieve maximum purity in a single step, affinity purification can be performed, using the antigen to provide specificity for the antibody. In this method, the antigen used to generate the antibody is covalently attached to an agarose support. If the antigen is a peptide, it is commonly synthesized with a terminal cysteine, which allows selective attachment to a carrier protein, such as KLH during development and to support purification. The antibody-containing medium is then incubated with the immobilized antigen, either in batch or as the antibody is passed through a column, where it selectively binds and can be retained while impurities are washed away. An elution with a low pH buffer or a more gentle, high salt elution buffer is then used to recover purified antibody from the support.
Antibody heterogeneity
Product heterogeneity is common in monoclonal antibodies and other recombinant biological products and is typically introduced either upstream during expression or downstream during manufacturing.[citation needed]
These variants are typically aggregates, deamidation products, glycosylation variants, oxidized amino acid side chains, as well as amino and carboxyl terminal amino acid additions.[24] These seemingly minute structural changes can affect preclinical stability and process optimization as well as therapeutic product potency, bioavailability and immunogenicity. The generally accepted purification method of process streams for monoclonal antibodies includes capture of the product target with protein A, elution, acidification to inactivate potential mammalian viruses, followed by ion chromatography, first with anion beads and then with cation beads.[citation needed]
Recombinant
The production of
Chimeric antibodies
While mouse and human antibodies are structurally similar, the differences between them were sufficient to invoke an immune response when
Recombinant DNA has been explored since the late 1980s to increase residence times. In one approach called "CDR grafting",[32] mouse DNA encoding the binding portion of a monoclonal antibody was merged with human antibody-producing DNA in living cells. The expression of this "chimeric" or "humanised" DNA through cell culture yielded part-mouse, part-human antibodies.[33][34]
Human antibodies
Ever since the discovery that monoclonal antibodies could be generated, scientists have targeted the creation of fully human products to reduce the side effects of humanised or chimeric antibodies. Several successful approaches have been proposed: transgenic mice,[35] phage display[16] and single B cell cloning.[15]
Cost
Monoclonal antibodies are more expensive to manufacture than small molecules due to the complex processes involved and the general size of the molecules, all in addition to the enormous research and development costs involved in bringing a new chemical entity to patients. They are priced to enable manufacturers to recoup the typically large investment costs, and where there are no price controls, such as the United States, prices can be higher if they provide great value. Seven University of Pittsburgh researchers concluded, "The annual price of mAb therapies is about $100,000 higher in oncology and hematology than in other disease states", comparing them on a per patient basis, to those for cardiovascular or metabolic disorders, immunology, infectious diseases, allergy, and ophthalmology.[36]
Applications
Diagnostic tests
Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence of this substance. Proteins can be detected using the Western blot and immuno dot blot tests. In immunohistochemistry, monoclonal antibodies can be used to detect antigens in fixed tissue sections, and similarly, immunofluorescence can be used to detect a substance in either frozen tissue section or live cells.
Analytic and chemical uses
Antibodies can also be used to purify their target compounds from mixtures, using the method of immunoprecipitation.
Therapeutic uses
Therapeutic monoclonal antibodies act through multiple mechanisms, such as blocking of targeted molecule functions, inducing apoptosis in cells which express the target, or by modulating signalling pathways.[37][38][39]
Cancer treatment
One possible treatment for
MAbs approved by the FDA for cancer include:[41]
Autoimmune diseases
Monoclonal antibodies used for
Examples of therapeutic monoclonal antibodies
Monoclonal antibodies for research applications can be found directly from antibody suppliers, or through use of a specialist search engine like CiteAb. Below are examples of clinically important monoclonal antibodies.
Main category | Type | Application | Mechanism/Target | Mode |
---|---|---|---|---|
Anti- inflammatory |
infliximab[42] | inhibits TNF-α |
chimeric | |
adalimumab | inhibits TNF-α |
human | ||
ustekinumab |
|
blocks interleukin IL-12 and IL-23 | human | |
basiliximab[42] |
|
inhibits T cells |
chimeric | |
daclizumab[42] |
|
inhibits T cells |
humanized | |
omalizumab |
|
inhibits human immunoglobulin E (IgE) | humanized | |
Anti-cancer | gemtuzumab[42]
|
|
targets myeloid cell surface antigen CD33 on leukemia cells | humanized |
alemtuzumab[42] |
|
targets an antigen B-lymphocytes |
humanized | |
rituximab[42] |
|
targets phosphoprotein B lymphocytes |
chimeric | |
trastuzumab |
|
targets the HER2/neu (erbB2) receptor |
humanized | |
nimotuzumab |
|
EGFR inhibitor | humanized | |
cetuximab |
|
EGFR inhibitor | chimeric | |
panitumumab |
|
EGFR inhibitor | human | |
bevacizumab & ranibizumab |
|
inhibits VEGF | humanized | |
Anti-cancer and anti-viral | bavituximab[43] |
|
immunotherapy, targets phosphatidylserine[43] | chimeric |
Anti-viral |
|
immunotherapy, targets spike protein of SARS-CoV-2 | human | |
bamlanivimab/etesevimab[45] |
|
immunotherapy, targets spike protein of SARS-CoV-2 | human | |
Sotrovimab[46] |
|
immunotherapy, targets spike protein of SARS-CoV-2 | human | |
Other | palivizumab[42] |
|
inhibits an RSV fusion (F) protein | humanized |
abciximab[42] |
|
inhibits the receptor platelets |
chimeric |
COVID-19
In 2020, the monoclonal antibody therapies
As of December 2021, in vitro neutralization tests indicate monoclonal antibody therapies (with the exception of sotrovimab and tixagevimab/cilgavimab) were not likely to be active against the Omicron variant.[48]
Over 2021–22, two Cochrane reviews found insufficient evidence for using neutralizing monoclonal antibodies to treat COVID-19 infections.[49][50] The reviews applied only to people who were unvaccinated against COVID‐19, and only to the COVID-19 variants existing during the studies, not to newer variants, such as Omicron.[50]
Side effects
Several monoclonal antibodies, such as bevacizumab and cetuximab, can cause different kinds of side effects.[51] These side effects can be categorized into common and serious side effects.[52]
Some common side effects include:
Among the possible serious side effects are:[53]
- Anaphylaxis
- Bleeding
- Arterial and venous blood clots
- Autoimmune thyroiditis
- Hypothyroidism
- Hepatitis
- Heart failure
- Cancer
- Anemia
- Decrease in white blood cells
- Stomatitis
- Enterocolitis
- Gastrointestinal perforation
- Mucositis
See also
- List of monoclonal antibodies
References
- ^ Gelboin HV. "Cytochrome P450 Mediated Drug and Carcinogen Metabolism using Monoclonal Antibodies". home.ccr.cancer.gov. Archived from the original on 15 October 2004. Retrieved 2 April 2018.
- PMID 10542439.
- S2CID 19615695.
- PMID 7934322.
- S2CID 4171375.
- S2CID 45615711.
- ^ a b c Marks LV. "The Story of César Milstein and Monoclonal Antibodies". WhatisBiotechnology.org. Retrieved 23 September 2020.
- S2CID 4335569.
- PMID 30320408.
- PMID 17948113.
- PMID 7568130.
- PMID 25996440.
- PMID 16761719.
- ISBN 978-0309075114
- ^ PMID 30101214.
- ^ PMID 20635390.
- PMID 24503933.
- S2CID 43459065.
- PMID 17510706.
- PMID 19247287.
- PMID 19103878.
- PMID 24030440.
- PMID 19075686.
- S2CID 29689097.
- PMID 20818176.
- PMID 21700290.
- S2CID 5523554.
- PMID 31489367.
- PMID 11889896.
- ^ "Dr. George Pieczenik". LMB Alumni. MRC Laboratory of Molecular Biology (LMB). 17 September 2009. Archived from the original on 23 December 2012. Retrieved 17 November 2012.
- PMID 10831134.
- PMID 27667400.
- S2CID 4311503.
- PMID 11287236.
- PMID 7494109.
- PMID 29461857.
- S2CID 43781004.
- .
- .
- S2CID 10169378.
- ^ Takimoto CH, Calvo E. (1 January 2005) "Principles of Oncologic Pharmacotherapy" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management Archived 4 October 2013 at the Wayback Machine
- ^ ISBN 978-0443071454.
- ^ a b "Bavituximab - Avid Bioservices". AdisInsight. Springer Nature Switzerland AG.
- ^ a b "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 21 November 2020. Retrieved 21 November 2020. This article incorporates text from this source, which is in the public domain.
- ^ a b "FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 9 February 2021. Retrieved 10 February 2021. This article incorporates text from this source, which is in the public domain.
- ^ "Emergency Use Authorization letter" (PDF). U.S. Food and Drug Administration (FDA). 16 December 2021. Retrieved 6 January 2022. This article incorporates text from this source, which is in the public domain.
- ISSN 0190-8286. Retrieved 21 December 2021.
- S2CID 245442677.
- PMID 34473343.
- ^ PMID 35713300.
- ^ "Monoclonal antibodies to treat cancer". American Cancer Society. Retrieved 19 April 2018.
- ^ "Monoclonal antibody drugs for cancer: How they work". Mayo Clinic. Retrieved 19 April 2018.
- ^ a b Ogbru O (12 October 2022). Davis CP (ed.). "Monoclonal Antibodies: List, Types, Side Effects & FDA Uses (Cancer)". MedicineNet. Retrieved 19 April 2018.
Further reading
- Rajewsky K (November 2019). "The advent and rise of monoclonal antibodies". Nature. 575 (7781): 47–49. PMID 31686050.
- Kimball JA. "Monoclonal Antibodies". Kimball's Biology Pages.
External links
- Monoclonal+antibodies at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Antibodypedia, open-access virtual repository publishing data and commentary on any antibodies available to the scientific community.
- Antibody Purification Handbook Archived 5 December 2008 at the Wayback Machine